1. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. Issue 1 (January 2022) Authors: Ishola, David; Manno, Daniela; Afolabi, Muhammed O; Keshinro, Babajide; Bockstal, Viki; Rogers, Baimba; Owusu-Kyei, Kwabena; Serry-Bangura, Alimamy; Swaray, Ibrahim; Lowe, Brett; Kowuor, Dickens; Baiden, Frank; Mooney, Thomas; Smout, Elizabeth; Köhn, Brian; Otieno, Godfrey T; Jusu, Morrison; Fost... Journal: Lancet infectious diseases Issue: Volume 22:Issue 1(2022) Page Start: 97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Issue 1 (January 2022) Authors: Afolabi, Muhammed O; Ishola, David; Manno, Daniela; Keshinro, Babajide; Bockstal, Viki; Rogers, Baimba; Owusu-Kyei, Kwabena; Serry-Bangura, Alimamy; Swaray, Ibrahim; Lowe, Brett; Kowuor, Dickens; Baiden, Frank; Mooney, Thomas; Smout, Elizabeth; Köhn, Brian; Otieno, Godfrey T; Jusu, Morrison; Fost... Journal: Lancet infectious diseases Issue: Volume 22:Issue 1(2022) Page Start: 110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗